Company Enlivex Therapeutics Ltd. Deutsche Boerse AG
Equities
1BT
IL0011319527
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 EUR | +2.44% |
|
+5.00% | -45.22% |
Jun. 30 | Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired. | CI |
Jun. 24 | Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Oren Hershkovitz
CEO | Chief Executive Officer | 47 | 19-11-15 |
Dror Mevorach
FOU | Founder | 68 | 08-12-31 |
Director of Finance/CFO | 47 | 15-12-31 | |
Chief Operating Officer | - | - | |
Sigal Arad
HRO | Human Resources Officer | - | - |
Iris Tavor
LAW | General Counsel | - | - |
Einat Galamidi
PRN | Corporate Officer/Principal | - | 22-02-21 |
Oren Elmaliah
AUD | Comptroller/Controller/Auditor | 40 | 17-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Shai Novik
CHM | Chairman | 58 | 13-12-31 |
Avri Havron
BRD | Director/Board Member | 76 | 13-12-31 |
Brian Schwartz
BRD | Director/Board Member | 52 | 20-11-30 |
Roger Pomerantz
BRD | Director/Board Member | 67 | 22-05-22 |
Gili Hart
BRD | Director/Board Member | 49 | 13-12-31 |
Andrew Singer
BRD | Director/Board Member | 53 | 23-04-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 20,658,555 | 18,008,736 ( 87.17 %) | 0 | 87.17 % |
Company contact information
![address Enlivex Therapeutics Ltd.(1BT)](https://cdn.zonebourse.com/static/address/23067864.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+57.74% | 14.11B |
- Stock Market
- Equities
- ENLV Stock
- 1BT Stock
- Company Enlivex Therapeutics Ltd.